دورية أكاديمية
Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study.
| العنوان: | Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study. |
|---|---|
| المؤلفون: | de la Court JR; Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. j.delacourt@amsterdamumc.nl.; Division of Infectious Diseases, Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. j.delacourt@amsterdamumc.nl., Woudt SHS; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Schoffelen AF; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Heijmans J; Department of Haematology, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., de Jonge NA; Department of Haematology, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., van der Bruggen T; Department of Medical Microbiology, University Medical Centre Utrecht, University Utrecht, Utrecht, The Netherlands., Bomers MK; Division of Infectious Diseases, Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Lambregts MMC; Department of Infectious Diseases, Leiden University Medical Centre, Leiden University, Leiden, The Netherlands., Schade RP; Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Sigaloff KCE; Division of Infectious Diseases, Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. |
| مؤلفون مشاركون: | ISIS-AR study group |
| المصدر: | Annals of clinical microbiology and antimicrobials [Ann Clin Microbiol Antimicrob] 2022 Nov 28; Vol. 21 (1), pp. 54. Date of Electronic Publication: 2022 Nov 28. |
| نوع المنشور: | Multicenter Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 101152152 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-0711 (Electronic) Linking ISSN: 14760711 NLM ISO Abbreviation: Ann Clin Microbiol Antimicrob Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, [2002]- |
| مواضيع طبية MeSH: | Bacteremia*/drug therapy , Hematologic Neoplasms*/complications , Hematologic Neoplasms*/drug therapy, Humans ; Retrospective Studies ; Prospective Studies ; Carbapenems ; Ceftazidime |
| مستخلص: | Objectives: Among patients with haematological malignancy, bacteraemia is a common complication during chemotherapy-induced neutropenia. Resistance of gram-negative bacteria (GNB) to third-generation cephalosporins (3GC) is increasing. In order to explore the value of using surveillance cultures to guide empirical treatment e.g. choosing between carbapenem versus ceftazidime- we aimed to assess the distribution of pathogens causing bacteraemia in patients with haematological malignancy, and the proportion of 3GC-resistant GNB (3GC-R GNB) bacteraemia that was preceded by 3GC-R GNB colonization. Methods: Using 11 years of data (2008-2018) from the Dutch national antimicrobial resistance surveillance system, we assessed the prevalence of 3GC-R GNB in episodes of bacteraemia, and the proportion of 3GC-R GNB bacteraemia that was preceded by 3GC-R GNB colonization. Colonization was defined as availability of any GNB surveillance isolate in the year before, independent of the causative micro-organism (time-paired isolates). Results: We included 3887 patients, representing 4142 episodes of bacteraemia. GNB were identified in 715/4142 (17.3%), of which 221 (30.9%) were 3GC-R GNB. In 139 of these 221 patients a time-paired surveillance culture was available. In 76.2% (106/139) of patients these surveillance cultures already showed 3GC-R GNB isolates in the year prior to the culture date of the 3GC-R GNB positive blood isolate. Conclusions: This multi-centre study shows that in patients with haematological malignancy, the majority of 3GC-R GNB bacteraemia is preceded by 3GC-R GNB colonization. Prospective clinical studies are needed to assess the safety and benefits of the use of surveillance-cultures to guide empirical therapy to restrict the empirical use of carbapenems in this population. (© 2022. The Author(s).) |
| References: | Ann Hematol. 2008 Feb;87(2):139-45. (PMID: 17938926) Support Care Cancer. 2016 Jan;24(1):253-259. (PMID: 26014616) Haematologica. 2013 Dec;98(12):1826-35. (PMID: 24323983) Bone Marrow Transplant. 2008 Sep;42(5):345-9. (PMID: 18587437) J Antimicrob Chemother. 2014 Dec;69(12):3387-92. (PMID: 25103492) J Infect. 2018 Jan;76(1):20-37. (PMID: 29079323) Eur J Microbiol Immunol (Bp). 2015 Sep 18;5(3):199-204. (PMID: 26495130) J Infect. 2014 Apr;68(4):321-31. (PMID: 24370562) Eur J Haematol. 2014 Oct;93(4):302-8. (PMID: 24750350) Antimicrob Agents Chemother. 2012 May;56(5):2518-23. (PMID: 22314534) Int J Antimicrob Agents. 2007 Nov;30 Suppl 1:S51-9. (PMID: 17689933) J Infect. 2016 Oct;73(4):336-45. (PMID: 27404978) Lancet Infect Dis. 2017 Jan;17(1):78-85. (PMID: 27751772) Expert Rev Hematol. 2020 Aug;13(8):923-927. (PMID: 32574123) Transpl Infect Dis. 2015 Feb;17(1):33-8. (PMID: 25546740) Intensive Care Med. 2014 Aug;40(8):1173-4. (PMID: 24966064) Clin Infect Dis. 2017 Nov 13;65(11):1819-1828. (PMID: 29020364) Biol Blood Marrow Transplant. 2018 Jul;24(7):1476-1482. (PMID: 29501780) Euro Surveill. 2017 Nov;22(46):. (PMID: 29162208) J Antimicrob Chemother. 2011 Mar;66(3):657-63. (PMID: 21193475) Clin Infect Dis. 2011 Feb 15;52(4):e56-93. (PMID: 21258094) Ann Hematol. 2020 Nov;99(11):2547-2553. (PMID: 32974837) Clin Microbiol Infect. 2014 Jan;20(1):O7-12. (PMID: 23826912) Clin Infect Dis. 2017 Nov 13;65(11):1884-1896. (PMID: 29020286) Antimicrob Agents Chemother. 1986 Sep;30(3):435-9. (PMID: 3640591) Cancer. 2006 May 15;106(10):2258-66. (PMID: 16575919) Ann Hematol. 2019 May;98(5):1051-1069. (PMID: 30796468) Clin Infect Dis. 2018 Nov 13;67(11):1720-1728. (PMID: 29701766) Infection. 2012 Dec;40(6):613-9. (PMID: 22665143) |
| فهرسة مساهمة: | Investigator: JWTC Stuart; DC Melles; K van Dijk; A Alzubaidy; BFM Werdmuller; GJ Blaauw; BMW Diederen; HJ Alblas; WA der Kuil; SM Bierman; SC de Greeff; SR Groenendijk; R Hertroys; EJ Kuijper; JC Monen; DW Notermans; WJ van den Reek; AE Smilde; CCH Wielders; RE Zoetigheid; W van den Bijllaardt; EM Kraan; EE Mattsson; JM da Silva; E de Jong; B Maraha; GJ van Asselt; A Demeulemeester; BB Wintermans; M van Trijp; A Ott; J Sinnige; DC Melles; W Silvis; LJ Bakker; JW Dorigo-Zetsma; K Waar; AT Bernards; MAL Hall; E Schaftenaar; MH Nabuurs-Franssen; H Wertheim; BMW Diederen; L Bode; M van Rijn; S Dinant; O Pontesilli; P de Man; M Wong; AE Muller; NH Renders; RG Bentvelsen; AGM Buiting; ALM Vlek; AJ Stam; A Troelstra; ITMA Overdevest; MPA van Meer; CO Dos Santos; MJHM Wolfhagen Keywords: Antimicrobial resistance; Colonization.; Empirical antibiotic therapy; Febrile neutropenia; Resistance surveillance; Third-generation-cephalosporin resistance |
| المشرفين على المادة: | 0 (Carbapenems) 9M416Z9QNR (Ceftazidime) |
| تواريخ الأحداث: | Date Created: 20221129 Date Completed: 20221130 Latest Revision: 20221202 |
| رمز التحديث: | 20221202 |
| مُعرف محوري في PubMed: | PMC9707019 |
| DOI: | 10.1186/s12941-022-00544-0 |
| PMID: | 36443758 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!